Monopar Therapeutics (MNPR) Institutional Ownership $0.72 +0.07 (+10.69%) (As of 07/26/2024 ET) Add Compare Share Share OwnershipStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Institutional Ownership Changes (13F Filings) for Monopar Therapeutics (NASDAQ:MNPR)CurrentInstitutional OwnershipPercentage1.83%Number ofInstitutional Buyers(last 12 months)1TotalInstitutional Inflows(last 12 months)$55.77KNumber ofInstitutional Sellers(last 12 months)0 Get MNPR Insider Trade Alerts Want to know when executives and insiders are buying or selling Monopar Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data MNPR Institutional Buying and Selling by Quarter Ad Colonial MetalsCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.In answer to this issue, we have released a Special Report to the public. Monopar Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails10/31/2023Windsor Advisory Group LLC89,974$56K0.1%N/A0.635% 8/13/2021Geode Capital Management LLC28,761$169K0.0%+9.0%0.229% 8/13/2021Vanguard Group Inc.97,462$574K0.0%+116.2%0.775% 5/21/2021Citadel Advisors LLC12,479$77K0.0%N/A0.099% 5/18/2021Citadel Advisors LLC12,479$77K0.0%N/A0.099% 5/17/2021Royal Bank of Canada9,130$57K0.0%N/A0.073% 5/12/2021Northern Trust Corp36,001$223K0.0%-38.8%0.286% 5/12/2021Geode Capital Management LLC26,394$163K0.0%N/A0.210% 5/7/2021BlackRock Inc.11,229$70K0.0%+108.3%0.089% 2/11/2021Northern Trust Corp58,793$360K0.0%-9.2%0.513% 2/5/2021BlackRock Inc.5,391$33K0.0%+99.4%0.047% (Data available from 1/1/2016 forward) MNPR Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of MNPR shares? During the previous two years, the following institutional investors and hedge funds held shares of Monopar Therapeutics shares: Windsor Advisory Group LLC ($56K).Learn more on MNPR's institutional investors. What percentage of Monopar Therapeutics stock is owned by institutional investors? 1.83% of Monopar Therapeutics stock is owned by institutional investors. Learn more on MNPR's institutional investor holdings. Which institutional investors have been buying Monopar Therapeutics stock? The following institutional investors have purchased Monopar Therapeutics stock in the last 24 months: Windsor Advisory Group LLC ($89.97K). How much institutional buying is happening at Monopar Therapeutics? Institutional investors have bought a total of 89,974 shares in the last 24 months. This purchase volume represents approximately $55.77K in transactions. Related Companies: Edesa Biotech Major Shareholders Reneo Pharmaceuticals Major Shareholders Lantern Pharma Major Shareholders Carisma Therapeutics Major Shareholders Kezar Life Sciences Major Shareholders Marker Therapeutics Major Shareholders Fortress Biotech Major Shareholders NextCure Major Shareholders YS Biopharma Major Shareholders Lexaria Bioscience Major Shareholders This page (NASDAQ:MNPR) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored4 Steps to Survive the Coming Market CrashCracks threaten us with a widespread collapse unlike anything we've seen in our lifetime. During this prese...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monopar Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Monopar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.